Open access · CC-BY
via OpenAlex
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Hilary Grosso Jasutkar, Stephanie E. Oh, M. Maral Mouradian
Pharmacological Reviews · 2022 · ▲ 100 citations
Abstract
-synuclein as a key pathogenic protein in this disease as well as in dementia with Lewy bodies, making it of leading therapeutic interest. This review discusses the various approaches being investigated and progress made to date toward discovering and developing therapeutics that would slow and stop progression of these disabling diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1124/pharmrev.120.000133
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
Jasutkar, H.G., Oh, S.E., & Mouradian, M.M. (2022). Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. <em>Pharmacological Reviews</em>. https://doi.org/10.1124/pharmrev.120.000133
Vancouver
Jasutkar HG, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. Pharmacological Reviews. 2022. doi:10.1124/pharmrev.120.000133.
BibTeX
@article{hilary2022Therap,
title = {Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease},
author = {Hilary Grosso Jasutkar and Stephanie E. Oh and M. Maral Mouradian},
journal = {Pharmacological Reviews},
year = {2022},
doi = {10.1124/pharmrev.120.000133},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alzheimer s Research & Therapy 2014
Open access · CC-BY
Alpha-synuclein biology in Lewy body diseases
Acta Medica 2021
Open access · CC-BY
An Overview of Alpha Synuclein Protein and Its Role in Parkinson’s disease
International journal of high school research 2025
Open access · OA
Disease Modification: Comparing Diverse Approaches to Alpha-Synuclein Targeting Therapies in Parkinson’s Disease
Pharmacological Research 2008
Preprint · OA
α-Synuclein: A therapeutic target for Parkinson’s disease?
Parkinson s Disease 2016
Open access · CC-BY
Alpha-Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application
Handbook of clinical neurology 2022
Preprint · OA